Rising Biosciences (Rising Biosciences) Operating Cash Flow per Share : $ (TTM As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Operating Cash Flow per Share?

Rising Biosciences's operating cash flow per share for the three months ended in . 20 was $0.00. Rising Biosciences does not have enough years/quarters to calculate the operating cash flow per share for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Rising Biosciences's Operating Cash Flow per Share or its related term are showing as below:

RBII's 3-Year OCF Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.55
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

Rising Biosciences Operating Cash Flow per Share Historical Data

The historical data trend for Rising Biosciences's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Operating Cash Flow per Share Chart

Rising Biosciences Annual Data

Trend

Operating Cash Flow per Share

Rising Biosciences Quarterly Data

Operating Cash Flow per Share

Competitive Comparison of Rising Biosciences's Operating Cash Flow per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rising Biosciences's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's Price-to-Operating-Cash-Flow falls into.

Rising Biosciences Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Rising Biosciences's Operating Cash Flow per Share for the fiscal year that ended in . 20 is calculated as

Operating Cash Flow per Share (A: . 20 )	=	Cash Flow from Operations (A: . 20 )	/	Shares Outstanding (Diluted Average) (A: . 20 )
	=		/	0
	=

Rising Biosciences's Operating Cash Flow per Share for the quarter that ended in . 20 is calculated as

Operating Cash Flow per Share (Q: . 20 )	=	Cash Flow from Operations (Q: . 20 )	/	Shares Outstanding (Diluted Average) (Q: . 20 )
	=		/	0
	=

Rising Biosciences Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Operating Cash Flow per Share

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.